PRE TEST CERVICAL SCREENING MANAGEMENT COLPOSCOPY PATHOLOGIC DIAGNOSIS AND TREATMENT

Similar documents
COLPOSCOPY MADE EASY AND SIMPLE

Appropriate Use of Cytology and HPV Testing in the New Cervical Cancer Screening Guidelines

HPV and Cervical Cancer, Screening and Prevention. John Ragsdale, MD July 12, 2018 CME Lecture Series

Faculty Pap Smear Guidelines: Family Planning Update 2008 Part Two

Dysplasia: layer of the cervical CIN. Intraepithelial Neoplasia. p16 immunostaining. 1, Cervical. Higher-risk, requires CIN.

Becoming a colposcopist: Colposcope case studies

Cervical Conization. 1

Chapter 10: Pap Test Results

Management Algorithms for Abnormal Cervical Cytology and Colposcopy

Management of Abnormal Cervical Cytology and Histology

CERVICAL INTRAEPITHELIAL NEOPLASIA (CIN)

Gynecologic Malignancies. Kristen D Starbuck 4/20/18

Eradicating Mortality from Cervical Cancer

Done by khozama jehad. Neoplasia of the cervix

Vaginal intraepithelial neoplasia

The society for lower genital tract disorders since 1964.

LABORATORY - PELVIC EXAM STUDIES COLPOSCOPY RESULTS FORM L14

Twenty-first refresher course. Chan Kit Sheung

Cervical Cancer Screening for the Primary Care Physician for Average Risk Individuals Clinical Practice Guidelines. June 2013

3/25/2019. Rare uterine cancers ~3% Leiomyosarcoma Carcinosarcoma (MMMT) Endometrial Stromal Sarcomas Aggressive tumors High Mortality Rates

!"#$%&'(#)*$+&,$-&.#,$/#0()1-$ ),1')$2(%&,2#,%$%(0'#$34567$

Your Colposcopy Visit

Clinical Practice Guidelines June 2013

Making Sense of Cervical Cancer Screening

Colposcopy. Attila L Major, MD, PhD

What is cervical cancer?

Case Based Problems. Recommended Guidelines. Workshop: Case Management of Abnormal Pap Smears and Colposcopies. Disclosure

Cervical Dysplasia and HPV

I have no financial interests to disclose.

Cervical Cancer Screening Update. Melissa Hartman, DO Women s Health

NAACCR Webinar Series /7/17

Cervical cancer presentation

I have no financial interests in any product I will discuss today.

Scottish Cervical Screening Programme. Colposcopy and Programme Management

Proposed new national cervical screening program. Dr Elizabeth Jackson Obstetrician Gynaecologist Cairns

VIN/VAIN O C T O B E R 3 RD J M O R G A N

Endometrial Cancer. Incidence. Types 3/25/2019

Clinical Guidance: Recommended Best Practices for Delivery of Colposcopy Services in Ontario Best Practice Pathway Summary

What is a Pap smear?

Michael G. Kelly, MD Gynecologic Oncologist University of Colorado Cancer Center

Female Genital Tract Lab. Dr. Nisreen Abu Shahin Assistant Professor of Pathology University of Jordan

1.Acute and Chronic Cervicitis - At the onset of menarche, the production of estrogens by the ovary stimulates maturation of the cervical and vaginal

LABORATORY - PELVIC EXAM STUDIES COLPOSCOPY RESULTS FORM L14

BCCCP Approved ICD-9 Code List Fiscal Year 2010

MPH Quiz. 1. How many primaries are present based on this pathology report? 2. What rule is this based on?

Gynecological Cancers in Primary Care

Gynecological Cancers

Cervical Skills. Dr Margaret Laing Queen Elizabeth University Hospital

Pap Smears Pelvic Examinations Well Woman Examinations. When should you have them performed???

ASCCP 2013 Guidelines for Managing Abnormal Cervical Cancer Screening Tests

Cervical Cancer 3/25/2019. Abnormal vaginal bleeding

Samuel B. Wolf, D.O., F.A.C.O.G. Emerald Coast Obstetrics and Gynecology Panama City Florida

New Cancer Cases By Site Breast 28% Lung 14% Colo-Rectal 10% Uterus 6% Thyroid 5% Lymphoma 4% Ovary 3%

Objectives. I have no financial interests in any product I will discuss today. Cervical Cancer Screening Guidelines: Updates and Controversies

WOMEN S INTERAGENCY HIV STUDY LABORATORY - PELVIC EXAM STUDIES COLPOSCOPY RESULTS FORM L14

The Pap Smear Test. The Lebanese Society of Obstetrics and Gynecology. Women s health promotion series

LABORATORY - PELVIC EXAM STUDIES COLPOSCOPY RESULTS FORM L14

Estimated New Cancers Cases 2003

HIV and AIDS Related Cancers DR GORDON AMBAYO UHS

Please complete prior to the webinar. HOSPITAL REGISTRY WEBINAR FEMALE REPRODUCTIVE SYSTEM EXERCISES CASE 1: FEMALE REPRODUCTIVE

Cervical Screening for Dysplasia and Cancer in Patients with HIV

GLANDULAR LESIONS PITFALLS IN MANAGEMENT. Dr Li Wai Hon HKSCCP The 15 th Anniversary Symposium 10 December 2016

Conflict of Interest Disclosure. Anita L. Nelson, MD. Principles Underlying Screening Recommendations. Learning Objectives

X-Treme Primary Care: HPV and STIs. Arti Barnes MD MPH Clinical Director South Central AIDS Education and Training Centers

WOMEN S INTERAGENCY HIV STUDY LABORATORY - PELVIC EXAM STUDIES TREATMENT FORM FORM L16

PREVENTION OF CERVICAL CANCER

Introduction to Colposcopy

BC Cancer Cervix Screening 2015 Program Results. February 2018

What is a Pap Smear and What do the results mean? Maria E Daheri RN Cervical Nurse Case Harris Health System

CLEAR COVERAGE HYSTERECTOMY CHECKLISTS

Molly A. Brewer DVM, MD, MS Chair and Professor Department of Obstetrics and Gynecology University of Connecticut School of Medicine

Case Study 1. Cervical Cancer Screening and Sexually Transmitted Infections Case Studies

One of the commonest gynecological cancers,especially in white Americans.

GUIDELINE FOR SCREENING FOR CERVICAL CANCER: REVISED

Cervical Cancer Screening Guidelines Update

Cytology Update M Laing QEUH

The Case of Mrs. Virginia Jones* Asst. Professor Division of Gyne-Oncology University of British Columbia, Department of Gynecology Vancouver, Canada

Understanding Your Pap Test Results

Colposcopic evaluation of cervical erosion in symptomatic women

CERVICAL CANCER FACTSHEET. What is cervical cancer?

Ritu Salani, M.D., M.B.A. Assistant Professor, Dept. of Obstetrics & Gynecology Division of Gynecologic Oncology The Ohio State University

Jacqui Morgan March 6, 2019

Cervical Cancer 4/27/2016

Screening for Cervical Cancer: Demystifying the Guidelines DR. NEERJA SHARMA

and endometrial cancers

Most common cancer Africans & Asians more prone because of poor socioeconomic condition Drastic decline in west as more detection of preinvasive

Cervical Precancer: Evaluation and Management

Diagnostically Challenging Cases in Gynecologic Pathology

SESSION J4. What's Next? Managing Abnormal PAPs in 2014

Cytology/Biopsy/Leep Gynecologic Correlation: Practical Considerations and Approaches.

What Causes Cervical Cancer? Symptoms of Cervical Cancer

Cervical Cancer - Suspected

4 Mousa Al-abbadi. Ola Al-juneidi. Abdul-rahman Ibrahim

ARRO Case: Early-stage Endometrial Cancer

Cervical Cancer : Pap smear

A GLIMPSE INTO A DAY OF WOMEN S HEALTH CARE. Lesley K. Bicanovsky, DO Cleveland Clinic 24 January 2015 CAOM 50th Annual January Seminar

I have no financial interests in any product I will discuss today.

Colposcopic Principles. Simon Leeson Consultant Obstetrician/ Gynaecologist Betsi Cadwaladr University Health Board UK

reproductive organs. Malignant neoplasms. 4. Inflammatory disorders of female reproductive organs 2 5. Infertility. Family planning.

Screening for the Precursors of Cervical Cancer in the Era of HPV Vaccination. Dr Stella Heley Senior Liaison Physician Victorian Cytology Service

Transcription:

PRE TEST CERVICAL SCREENING MANAGEMENT COLPOSCOPY PATHOLOGIC DIAGNOSIS AND TREATMENT QUESTION #1 WHICH OF THE FOLLOWING IS NOT A RISK FACTOR FOR CERVICAL CANCER? A. HIGH RISK HPV B. CIGARETTE SMOKING C. MULTIPARITY D. FAMILY HISTORY OF CERVICAL CANCER E. EARLY AGE AT FIRST SEXUAL INTERCOURSE 1

QUESTION #2 WHICH OF THE FOLLOWING IS THE HIGHEST RISK FOR ADENOCARCINOMA OF THE CERVIX? A. HPV 18 B. HPV 31 C. HPV 16 D. HPV 33 E. HPV 22 QUESTION #3 HOW SHOULD WOMEN WITH UNSATISFACTORY CYTOLOGY TEST RESULTS BE MANAGED? A. REPEAT PAP SMEAR IN ONE YEAR B. REPEAT PAP IMMEDIATELY C. NO NEED TO REPEAT PAP D. REPEAT PAP SMEAR IN 2-4 MONTHS E. IMMEDIATE COLPOSCOPY 2

QUESTION #4 FOR EACH OF THE FOLLOWING SCENARIOS, INDICATE THE APPROPRIATED FOLLOW UP TESTING A 38 YO WITH 2 CONSECUTIVES UNSATISFACTORY CYTOLOGY RESULTS A. REPEAT CYTOLOGY IN ONE YEAR B. REPEAT CO-TESTING IN ONE YEAR C. ROUTINE SCREENING D. COLPOSCOPY QUESTION #5 FOR EACH OF THE FOLLOWING SCENARIOS, INDICATE THE APPROPRIATED FOLLOW UP TESTING A 36 YO WITH NEGATIVE CYTOLOGY AND A POSITIVE HPV CO TEST A. REPEAT CYTOLOGY IN ONE YEAR B. REPEAT CO-TESTING IN ONE YEAR C. ROUTINE SCREENING D. COLPOSCOPY 3

QUESTION #6 FOR EACH OF THE FOLLOWING SCENARIOS, INDICATE THE APPROPRIATED FOLLOW UP TESTING A 24YO WITH TWO LGSIL PAPS 12 MONTHS APART AND NEGATIVE REFLEX HPV TESTING A. REPEAT CYTOLOGY IN ONE YEAR B. REPEAT CO-TESTING IN ONE YEAR C. ROUTINE SCREENING D. COLPOSCOPY QUESTION #7 FOR EACH OF THE FOLLOWING SCENARIOS, INDICATE THE APPROPRIATED FOLLOW UP TESTING A 32 YO WOMAN WITH NEGATIVE CYTOLOGY HPV POSITIVE CONTESTING, AND REFLEX GENOTYPING POSITIVE FOR HPV 16 A. REPEAT CYTOLOGY IN ONE YEAR B. REPEAT CO-TESTING IN ONE YEAR C. ROUTINE SCREENING D. COLPOSCOPY 4

QUESTION #8 FOR EACH OF THE FOLLOWING SCENARIOS, INDICATE THE APPROPRIATED FOLLOW UP TESTING A 19YO WITH HGSIL A. REPEAT CYTOLOGY IN ONE YEAR B. REPEAT CO-TESTING IN ONE YEAR C. ROUTINE SCREENING D. COLPOSCOPY QUESTION #9 FOR EACH OF THE FOLLOWING SCENARIOS, INDICATE THE APPROPRIATED FOLLOW UP TESTING A 24YO WITH ASCUS-US CYTOLOGY AND NEGATIVE REFLEX HPV TESTING A. REPEAT CYTOLOGY IN ONE YEAR B. REPEAT CO-TESTING IN ONE YEAR C. ROUTINE SCREENING D. COLPOSCOPY 5

QUESTION #10 FOR EACH OF THE FOLLOWING SCENARIOS, INDICATE THE APPROPRIATED FOLLOW UP MANAGEMENT A 62 YO WITH AGC CYTOLOGY A. COLPOSCOPY B. COLPOSCOPY + EMB C. REFLEX HPV TESTING D. REPEAT CYTOLOGY IN 1 YEAR QUESTION 11-13 A 54-YEAR-OLD MULTIPAROUS WOMAN WAS REFERRED FOR COLPOSCOPY BECAUSE OF AN ABNORMAL CERVICAL CYTOLOGIC SMEAR. THE CERVIX APPEARED GROSSLY NORMAL. AFTER APPLICATION OF 3% ACETIC ACID, COLPOSCOPICALLY-DIRECTED BIOPSY WAS TAKEN OF AN AREA OF ACETOWHITE EPITHELIUM WITH MOSAICISM AND PUNCTATION. THE BIOPSY SPECIMEN MEASURED 2.8 MM FROM THE EPITHELIAL SURFACE TO THE DEEP MARGIN. (PLEASE SEE ILLUSTRATION). WHICH OF THE FOLLOWING IS THE MOST LIKELY DIAGNOSIS? A. CHRONIC CERVICITIS B. LOW-GRADE SQUAMOUS INTRAEPITHELIAL LESION (LSIL) C. HIGH-GRADE SQUAMOUS INTRAEPITHELIAL LESION (HSIL) D. INVASIVE CERVICAL CANCER 6

QUESTION 11-13 WHICH HUMAN PAPILLOMA VIRUS (HPV) SUBTYPE IS MOST COMMONLY ASSOCIATED WITH THIS LESION? A. 6 B. 11 C. 16 D. 33 QUESTIONS 11-13 WHAT IS THE MOST APPROPRIATE NEXT STEP IN MANAGEMENT OF THIS PATIENT? A. REPEAT CERVICAL CYTOLOGY IN 4 MONTHS B. HPV DNA TESTING FOR HIGH-RISK SUBTYPES C. CERVICAL CONIZATION D. RADICAL HYSTERECTOMY WITH PELVIC AND PARAAORTIC LYMPHADENECTOMY 7

QUESTION #14 A 63-YEAR-OLD WOMAN, G 5 P 4014 REQUESTS EVALUATION BECAUSE OF A CHRONIC HISTORY OF VULVAR AND PERINEAL PRURITUS AND PAIN. SHE HAS BEEN TREATED WITH SHORT COURSES OF MEDICATION FOR RECURRENT YEAST INFECTIONS, WHICH HAS RESULTED IN PARTIAL RELIEF OF HER SYMPTOMS. THE PHOTOGRAPH ILLUSTRATES THE PRESENT APPEARANCE OF HER VULVA. WHICH OF THE FOLLOWING IS THE MOST APPROPRIATE NEXT STEP IN MANAGEMENT OF THIS PATIENT? A. COLPOSCOPY B. LONG-TERM ANTIFUNGAL MEDICATION C. HIGH POTENCY TOPICAL STEROIDS D. MULTIPLE PUNCH BIOPSIES E. WIDE LOCAL EXCISION QUESTIONS #15-17 A 45 YEAR OLD WOMAN, P3003 PRESENTED WITH A "FLESHY BULGE" PROTRUDING FROM HER VAGINA. SHE ALSO REPORTED OCCASIONAL INTERMENSTRUAL AND POSTCOITAL SPOTTING. OTHERWISE, SHE HAD REGULAR MENSES AND NO HISTORY OF ABNORMAL PAP SMEARS. HER LAST PAP SMEAR WAS 13 MONTHS AGO, AND HER URINE PREGNANCY TEST WAS NEGATIVE. ON SPECULUM EXAMINATION, A SMOOTH, SOFT, ERYTHEMATOUS 8 CM X 1 CM LESION (SEE FIGURE 1) PROTRUDED FROM THE CERVICAL OS AND EXTENDED TO THE INTROITUS. THE REST OF THE VAGINA AND CERVIX APPEARED NORMAL. THE EXTERNAL OS WAS DILATED APPROXIMATELY 1 CM, AND THE BASE OF THE STALK OF THE LESION WAS PALPATED APPROXIMATELY 2 CM DISTAL TO THE CERVICAL OS. ON BIMANUAL EXAMINATION, HER UTERUS, CERVIX, AND ADNEXAE WERE NONTENDER. 8

QUESTIONS #15-17 WHICH ONE OF THE FOLLOWING LESIONS IS THE LEAST LIKELY DIAGNOSIS? A. RETAINED PRODUCTS OF CONCEPTION B. ENDOCERVICAL POLYP C. ENDOMETRIAL POLYP D. PROLAPSING MYOMA E. CERVICAL CANCER 9

QUESTONS 15-17 WHICH OF THE FOLLOWING SHOULD NOT BE PART OF THE INITIAL MANAGEMENT OF THIS PATIENT? A. PAP SMEAR B. COLPOSCOPY C. AVULSION OF THE POLYP WITH A FORCEPS AND HISTOLOGIC EVALUATION D. ENDOMETRIAL BIOPSY QUESTIONS 15-17 WHAT IS THE APPROXIMATE PROBABILITY THAT THIS LESION IS MALIGNANT? A. 25% B. 14% C. 5% D. 0.5% 10

QUESTIONS #18-21 A 40-YEAR-OLD WOMAN PRESENTS TO YOUR OFFICE WITH A COMPLAINT OF POSTCOITAL SPOTTING. HER EXTERNAL GENITALIA AND VAGINAL AND CERVICAL MUCOSA APPEAR GROSSLY NORMAL ON EXAMINATION. BIMANUAL EXAMINATION DEMONSTRATES A NON-TENDER, AXIAL, FREELY MOBILE UTERUS, APPROXIMATELY 10 WEEKS SIZE, AND NO ADNEXAL MASSES OR TENDERNESS. THE PAP SMEAR AND CULTURES THAT YOU PERFORM ARE NEGATIVE. THE PATIENT CONTINUES TO COMPLAIN OF POSTCOITAL SPOTTING, AND YOU PERFORM A HYSTEROSCOPY. THE KEY INTRAOPERATIVE FINDING IS SHOWN IN THE PHOTOGRAPH. QUESTIONS 18-21 11

QUESTIONS # 18-21 THIS TYPE OF UTERINE LESION IS MOST COMMON IN WHAT AGE GROUP? A. 10 TO 19 YEARS OLD B. 20 TO 29 YEARS OLD C. 40 TO 49 YEARS OLD D. OVER 60 YEARS OLD QUESTIONS # 18-21 FROM WHAT AREA OF THE UTERUS ARE THESE LESIONS MOST LIKELY TO ARISE? A. FUNDUS B. CORPUS C. CERVIX 12

QUESTIONS 18-21 WHICH MEDICATION IS MOST LIKELY TO BE ASSOCIATED WITH THIS LESION? A. ORAL CONTRACEPTIVES B. DEPOT-LUPRON C. TAMOXIFEN D. MEDROXYPROGESTERONE ACETATE QUESTIONS # 18-21 IF MALIGNANT CHANGE OCCURS WITHIN THIS LESION, IT IS USUALLY ASSOCIATED WITH WHAT STAGE/GRADE OF ENDOMETRIAL CANCER? A. IA B. IC C. II D. IV 13

QUESTIONS # 22-24 A 58-YEAR-OLD WOMAN, G 3 P 2103, REQUESTED EVALUATION BECAUSE OF POSTMENOPAUSAL BLEEDING. HER PHYSICAL EXAMINATION WAS NORMAL. HER PAP SMEAR IS SHOWN IN FIGURE 1. HER ENDOMETRIAL BIOPSY IS SHOWN IN FIGURE 2 QUESTIONS #22-24 WHAT TYPE OF CELLS ARE SEEN IN THE PAP SMEAR? A. MALIGNANT SQUAMOUS CELLS B. MALIGNANT ENDOMETRIAL CELLS C. DYSPLASTIC SQUAMOUS CELLS D. NORMAL ENDOCERVICAL CELLS 14

QUESTIONS 22-24 WHAT FINDING IS ILLUSTRATED ON THE ENDOMETRIAL BIOPSY? A. ENDOMETRIAL CARCINOMA B. CLEAR CELL CARCINOMA C. PAPILLARY SEROUS CARCINOMA D. ADENOSQUAMOUS CARCINOMA QUESTIONS # 22-24 WHICH OF THE FOLLOWING IS THE MOST APPROPRIATE TREATMENT FOR THIS PATIENT? A. TAH, BSO, OMENTECTOMY B. TAH, BSO, PELVIC LYMPHADENECTOMY C. TAH, BSO, PELVIC AND AORTIC LYMPHADENECTOMY D. TAH, BSO, OMENTAL BIOPSY, PELVIC AND AORTIC LYMPHADENECTOMY 15